C07D 515/08
Bridged systems
C07D515/08 (Bridged systems) appears on 21 US grants and 33 published applications in this corpus.
Search patents in C07D- Granted patents
- 21
- Published applications
- 33
- Assignees
- 26
- Inventors
- 146
- Latest grant
- 23 Sep 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 0 |
| 2004 | 0 | 0 |
| 2005 | 1 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 1 | 3 |
| 2012 | 0 | 0 |
| 2013 | 1 | 1 |
| 2014 | 1 | 0 |
| 2015 | 0 | 1 |
| 2016 | 1 | 2 |
| 2017 | 2 | 3 |
| 2018 | 3 | 3 |
| 2019 | 4 | 1 |
| 2020 | 0 | 0 |
| 2021 | 1 | 0 |
| 2022 | 1 | 4 |
| 2023 | 0 | 6 |
| 2024 | 0 | 2 |
| 2025 | 1 | 4 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Cystic fibrosis transmembrane conductance regulator modulating agents23 Sep 2025US 12,421,251 B2Vertex Pharmaceuticals Incorporated
- Tricyclic inhibitors of Hepatitis B virus22 Nov 2022US 11,504,382 B2Antios Therapeutics, Inc.
- Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 231 Aug 2021US 11,104,690 B2Merck Sharp & Dohme Corp.
- Modified macrocyclic compounds26 Feb 2019US 10,214,542 B2Bayer Pharma Aktiengesellschaft
- Therapeutic compounds12 Feb 2019US 10,202,360 B2Celgene Quanticel Research, Inc.
- Compounds for treating cancer16 Jul 2026US 2026/0200943 A1Genesis Therapeutics, Inc.
- Modulators of cystic fibrosis transmembrane conductance regulator6 Nov 2025US 2025/0340574 A1Vertex Pharmaceuticals Incorporated
- Macrocyclic inhibitors of atp citrate lyase18 Sep 2025US 2025/0289793 A1Esperion Therapeutics, Inc.
- Atr inhibitors31 Jul 2025US 2025/0243220 A1Aprea Therapeutics AB
- MYST Inhibitors17 Apr 2025US 2025/0122182 A1Isosterix, Inc.
Most cited
By later US patents
- Fluorescent complex and lighting system using the same39US 7,902,741 B2Kabushiki Kaisha Toshiba · 2011
- Macrocyclics pyrimidines as aurora kinase inhibitors18US 8,815,872 B2Merck Patent GmbH · 2014
- Conformationally constrained, fully synthetic macrocyclic compounds7US 10,017,481 B2Polyphor AG · 2018
- Inhibitors of prenyl-protein transferase5US 6,413,964 B12002
- Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors4US 9,663,535 B2Atrin Pharmaceuticals LLC · 2017